We built an in-house oligonucleotide array on which 394 genes were selected based on our Serial Analysis of Gene Expression (SAGE) data and previously reported array data and listed several genes related to cancer progression. Among these, we focused on SEC11A, which encodes the SPC18 protein. SEC11A mRNA expression was measured by quantitative reverse transcriptionpolymerase chain reaction (qRT-PCR) in gastric cancer (GC) tissue samples. Expression and distribution of SPC18 protein were investigated by immunohistochemical analysis in two independent GC cohorts (Hiroshima cohort, n ¼ 99 and Chiba cohort, n ¼ 989). To determine the effect of SPC18 on cell viability and invasiveness in vitro, MTT and Boyden chamber invasion assays were performed. To evaluate the influence of SPC18 on cell growth in vivo, GC cells were injected into severe combined immunodeficiency mice. Levels of TGF-a and EGF in media from the GC cells were measured by enzyme-linked immunosorbent assay (ELISA). Studies in human tissue revealed overexpression of SEC11A mRNA in 40% of 42 GC samples by qRT-PCR. Immunohistochemical analysis of SPC18 revealed that 26 and 20% of GC cases were SPC18-positive in the Hiroshima and Chiba cohorts, respectively. In both cohorts, the Kaplan-Meier analysis showed poorer survival in SPC18-positive GC cases than in SPC18-negative GC cases. Forced expression of SPC18 activates GC cell growth in vitro and in vivo. The levels of TGF-a in culture media from GC cells were reduced by knockdown of SPC18. These results indicate that SPC18 contributes to malignant progression through promotion of TGF-a secretion in GC.
INTRODUCTION
Gastric cancer (GC) is one of the most common human cancers. Better knowledge of the changes in gene expression that occur during gastric carcinogenesis may lead to improvements in diagnosis, treatment and prevention of GC. 1 We previously performed Serial Analysis of Gene Expression (SAGE) on four primary GC tissues and identified several genes whose expression was either up-or downregulated in GC. 2, 3 Of these genes, regenerating islet-derived family, member 4 (REG4, which encodes Reg IV) and olfactomedin4 (OLFM4, also known as GW112 or hGC-1) were found to encode secreted proteins and serve as high sensitive serum markers for GC. 4, 5 However, expression of many genes remained unconfirmed, and their role in GC remains unclear.
In the present study, we built an in-house oligonucleotide array, on which 394 genes were selected based on our SAGE data and previously reported array data, in order to identify the genes of most relevance to gastric carcinogenesis. To build the array, first, 164 genes found to be upregulated or downregulated in GC were chosen based on our SAGE data. 2 Then, 120 genes related to GC progression or prognosis, and 110 genes related to chemosensitivity, were selected based on previous reports. [6] [7] [8] [9] Several genes associated with GC progression were identified using our array. Among these genes, the SEC11A was our focus, because it is frequently overexpressed in GC. SEC11A encodes the SPC18 protein, which is one of the subunits of the signal peptidase complex (SPC). Most secretory proteins contain amino terminal-or internal signal peptides that direct their sorting to the endoplasmic reticulum (ER). 10 From the ER, proteins are transported to either the extracellular space or the plasma membrane through the ER-Golgi secretory pathway. The ER signal peptides are then cleaved by the SPC. It has been reported that SPC purified from canine microsomes has five distinct subunits. 11 Two of these subunits, SPC18 and SPC21, are presumed to have catalytic activity. 12 It is possible that increased activity of SPC caused by SPC18 protein overexpression could induce secretion of several kinds of growth factors; however, the expression and function of SPC proteins including SPC18 have not been investigated in human cancers.
In this study, we analyzed the expression and distribution of SPC18 in human GC by immunohistochemical analysis and examined the relationship between SPC18 staining and clinicopathologic characteristics. We show first that SPC18 can increase GC cell viability in vitro and in vivo. Second, we show that knockdown of SPC18 by RNA interference (RNAi) inhibits transforming growth factor (TGF)-a secretion in GC cells. It has been reported that treatment with TGF-a induces expression of matrix metalloproteinase (MMP)-2, MMP-7 and urokinase-type plasminogen activator, which activates cancer cell invasion. 13 
RESULTS
Gene expression analysis by in-house oligonucleotide array The in-house oligonucleotide array was used to analyze a series of 25 GC tissue samples and their corresponding non-neoplastic mucosa samples. We found six genes whose expression was significantly higher in GC at stage III/IV than in GC at stage I/II, and five genes whose expression was significantly lower in GC at stage III/IV than in GC at stage I/II (Table 1) . To identify ideal biomarkers and therapeutic targets for GC, we focused on genes whose expression was higher in late-stage (stage III/IV) GC samples than those in early-stage (stage I/II) GC samples. Among these genes, expression of MMP-7, which encodes MMP-7 (matrilysin), was statistically the most strongly upregulated in late stage GC cases. This is consistent with previous reports that high MMP-7 expression is associated with invasion and metastasis of GC. 14 The gene with the second-highest upregulation was SEC11A. SEC11A encodes the SPC18 protein, which is an ER signal peptidase enzyme located on the ER membrane that cleaves signal peptides from precursor proteins following their transport out of the cytoplasmic space. 10 SPC consists of SPC12, SPC18, SPC21, SPC22/23 and SPC25; of these proteins, SPC18 and SPC21 are presumed to have catalytic activity based on their homology to characterized signal peptidases. 12 It is well known that several growth factors, such as TGF-a and epidermal growth factor (EGF), have an important role in GC progression. It is possible that increased SPC activity in GC caused by SPC18 upregulation could induce the secretion of several growth factors, such as TGF-a or EGF; however, to the best of our knowledge, expression of SPC18 in human cancers including GC has not yet been studied. Therefore, investigations into SEC11A expression in GC tissue may yield novel and informative data in the context of regulation of GC progression.
Although some of the genes on the in-house oligonucleotide array includes genes selected based on previously reported data, inconsistent results were obtained. For example, our in-house oligonucleotide array includes TERT gene because we previously reported that overexpression of TERT mRNA is found in 90% of GC cases. 15 However, of 25 GC cases analyzed by our in-house oligonucleotide array, only two GC cases showed overexpression (GC/corresponding non-neoplastic mucosa ratio42) of TERT mRNA. Therefore, we conclude that sensitivity of our in-house oligonucleotide array is low, and measurement of mRNA expression levels by qRT-PCR is required. Although our in-house oligonucleotide array showed a marginal 1.33-fold increase in SEC11A, we decided to investigate SEC11A expression in GC tissue. mRNA expression of SEC11A in GC tissue and non-neoplastic tissue samples We next investigated the expression of SEC11A in nine GC tissue samples and 12 types of normal tissue samples by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) (Figure 1a) . Overexpression (GC/normal stomach ratio42) of SEC11A was observed in 4 (44%) of 9 GC cases. Among the 12 types of normal tissue samples, the highest SEC11A expression was found in the bone marrow. However, within the nine GC cases, three cases showed SEC11A expression levels higher than those in the bone marrow. In the same tissue samples, we also investigated the expression of SEC11C (which encodes the SPC21 protein) because of its presumed catalytic activity. In contrast to SEC11A, overexpression (GC/normal stomach ratio42) of SEC11C was detected in 1 (11%) case. Expression of SEC11A was analyzed by qRT-PCR in 42 additional GC tissue samples and corresponding non-neoplastic mucosa samples (Figure 1b) . Overexpression (GC/ corresponding non-neoplastic mucosa ratio42) of SEC11A was observed in 17 (40%) of the 42 GC cases. Overexpression of SEC11A was more frequently found in stage III/IV GC cases (15/24, 63%) than in stage I/II GC cases (2/18, 11%, P ¼ 0.001, w 2 -test). These results suggest that, although both SEC11A and SEC11C encode subunits of SPC, their mRNA expression levels were regulated differently, and only SEC11A was overexpressed in GC cases (40%).
Expression and distribution of SPC18 protein in GC tissue
The polyclonal anti-SPC18 antibody generated in our laboratory was detected in a single band of B18-kDa on western blots of cell extracts from MKN-45 cells (Figure 2a) . We confirmed that SPC18 protein was also detected in extracts of the microsomal fraction, which included ER protein (Figure 2a) . Furthermore, the 18-kDa band disappeared with preincubation of the antibody with the appropriate SPC18 protein.
We performed immunohistochemical analysis of SPC18 in two independent cohorts: the Hiroshima and Chiba cohorts. First, immunohistochemical analysis was performed in the Hiroshima cohort using whole paraffin-embedded blocks to analyze in detail the expression and distribution of SPC18 protein in GC tissue. In non-neoplastic gastric mucosa, staining of SPC18 was either weak or absent in epithelial and stromal cells, whereas corresponding GC tissue showed relatively stronger, more extensive staining (Figure 2b ). SPC18 was detected in the cytoplasm of tumor cells in intestinal-type ( Figure 2c ) and diffuse-type GC (Figure 2d ). The percentage of SPC18-stained tumor cells ranged from 0 to 80%. We confirmed that specific immunostaining was not seen with pre-adsorbed anti-SPC18 antibody (data not shown). When more than 10% of tumor cells were stained, the immunostaining was considered positive for SPC18. In total, 26 (26%) of 99 GC cases were positive for SPC18. SPC18 staining was observed more frequently in stage III/IV cases than in stage I/II cases (P ¼ 0.002, w 2 -test, Table 2 ). We found that SPC18 expression was significantly associated with increased cancer-specific mortality (P ¼ 0.002, Logrank test, Figure 2e ). The univariate analysis indicated that expressions of SPC18 (Hazard ratio (HR), 2.71; 95% confidence interval (CI), 1.38-5.37; P ¼ 0.003) and tumor stage (HR, 9.62; 95% CI, 3.94-23.26; Po0.001) were associated with survival, while age, sex and histological classification were not. However, in the multivariate model, SPC18 expression was not an independent prognostic indicator ( Table 3) . Next, immunohistochemical analysis was performed in the Chiba cohort using tissue microarray. When more than 10% of tumor cells were stained, the immunostaining was considered positive for SPC18. In total, 197 (20%) of 989 GC cases were positive for SPC18. SPC18 staining was associated with tumor stage (Po0.001, w 2 -test, Table 4 ). We found that SPC18 expression was significantly associated with increased cancer-specific mortality (P ¼ 0.001, Log-rank test, Figure 2f ). The univariate analysis indicated that expression of SPC18 (HR, 1.73; 95% CI, 1.24-2.39; P ¼ 0.001) was associated with survival. However, in the multivariate model, SPC18 expression was not an independent prognostic indicator ( Table 5 ).
Forced expression of SPC18 promotes GC cell growth in vitro and in vivo The MKN-1 GC cell line was stably transfected with pcDNA-V5-SPC18. MKN-1 cells were selected for low SEC11A mRNA expression from among eight different GC cell lines (data not shown). Clones were selected in G418 and examined for SPC18 expression by V5 western blot (Figure 3a) . Clones that expressed V5-tagged SPC18 were designated as MKN-1-SPC18-1, MKN-1-SPC18-2 and MKN-1-SPC18-3. Endogenous and exogenous levels of SPC18 protein were also investigated in one western blot with anti-SPC18 antibody to demonstrate the relative overexpression of SPC18. As shown in Figure 3a , MKN-1-SPC18-1, MKN-1-SPC18-2 and MKN-1-SPC18-3 expressed V5-tagged SPC18 protein at significantly higher levels than MKN-1 cells transfected with empty vector. To determine the effect of SPC18 on cell viability in vitro, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were performed. On day 8, MKN-1 cells transfected with V5-tagged SPC18 showed significantly increased viability compared with MKN-1 cells transfected with pcDNA 3.1 control vector (P ¼ 0.001, P ¼ 0.001 and P ¼ 0.001, respectively, unpaired Student's t-test) (Figure 3b ). Boyden chamber invasion assays were then performed. V5-tagged SPC18-transfected MKN-1 cells were more invasive than cells transfected with control vector, as measured on day 2 (P ¼ 0.023 and P ¼ 0.015, and P ¼ 0.010. respectively, unpaired Student's t-test) (Figure 3c) .
We next hypothesized that increased activity of SPC by forced overexpression of SPC18 protein could induce secretion of several types of growth factor associated with cancer cell growth. EGF and TGF-a both phosphorylate the EGF receptor (EGFR) and stimulate multiple signaling pathways involved in cell proliferation, antiapoptosis and other processes. 16, 17 As measured by enzymelinked immunosorbent assay (ELISA), secretion of TGF-a was high in culture media from the MKN-1 cells stably transfected with pcDNA-V5-SPC18 in comparison with culture media from the MKN-1 cells transfected with pcDNA 3.1 control vector (P ¼ 0.001, P ¼ 0.001 and P ¼ 0.001, respectively, unpaired Student's t-test) (Figure 3d ). EGF protein, however, was not detected in culture media from MKN-1 cells transfected with pcDNA 3.1 control vector or those transfected with pcDNA-V5-SPC18.
SPC18 and SPC21 are presumed to have catalytic activity to cleave ER signal peptides during protein trafficking from the ER to the extracellular space or to the plasma membrane through the ER-Golgi secretory pathway. 12 This raises a question whether the catalytic activity of SPC18 is required for promoting TGF-a secretion. It has been reported that the high degree of sequence similarity between yeast Sec11p and its canine homologs, SPC18 and SPC21. 12 The alignment shows that canine SPC18 and SPC21 have conserved serine, histidine and aspartic acid residues that are known to be essential for Sec11p catalytic activity. However, catalytic activity of human SPC18 has not been investigated. To examine which part of the SPC18 protein mediates the signal peptidase activity, we generated a NH 2 -terminal and COOH-terminal truncation mutant constructs of SPC18 as a fusion protein containing a NH 2 -terminal V5 tag These results indicate that SCP18 is involved in maintaining TGF-a secretion in GC cells, and both NH 2 -terminal half of the SPC18 protein and COOH-terminal half of the SPC18 protein are required for TGF-a secretion.
It is possible that increased activity of SPC by SPC18 protein upregulation could induce secretion of several types of growth factor associated with cancer cell growth and invasion, and role of TGF-a in invasion remains unclear. Therefore, we asked whether TGF-a is involved in invasion activity in MKN-1 cells. Treatment with TGF-a stimulated the cell invasion activity of MKN-1 cells (P ¼ 0.001, unpaired Student's t-test) (Figure 3c ). However, as TGF-a also increased cell viability (P ¼ 0.025, unpaired Student's t-test) (Figure 3b) , the cell number difference observed in the invasion assay may be caused by increased cell proliferation activity.
To evaluate the influence of SPC18 on cellular growth in vivo, the MKN-1 cells stably transfected with pcDNA-V5-SPC18 were subcutaneously injected into the backs of severe combined immunodeficiency (SCID) mice. As shown in Figure 3f , tumor volume increased much faster in mice injected with MKN-1-SPC18-1 (n ¼ 5), MKN-1-SPC18-2 (n ¼ 5) and MKN-1-SPC18-3 (n ¼ 5) than in mice injected with MKN-1 cells transfected with control vector (n ¼ 5) (P ¼ 0.001, P ¼ 0.001 and P ¼ 0.001, respectively, unpaired Student's t-test). The Ki67 index in tumors injected with MKN-1-SPC18-1 was significantly higher than that in MKN-1 cells transfected with control vector (P ¼ 0.029, unpaired Student's t-test) on day 48 (Figure 3g ). The Ki67 index in tumors injected with MKN-1-SPC18-2 and with MKN-1-SPC18-3 was also significantly higher than that in MKN-1 cells transfected with control vector on day 48 (P ¼ 0.029 and P ¼ 0.029, respectively, unpaired Student's t-test). Because secretion of TGF-a was high in culture media from the MKN-1 cells stably transfected with pcDNA-V5-SPC18 in comparison with culture media from the MKN-1 cells transfected with pcDNA 3.1 control vector, phosphorylation of EGFR in mouse tumors on day 48 was examined by western blot (Figure 3h ). Phosphorylation of EGFR at Tyr1068 in tumors injected with MKN-1-SPC18-1, MKN-1-SPC18-2 and MKN-1-SPC18-3 was significantly higher than that in tumors injected with MKN-1 cells transfected with control vector. We also examined the activation of downstream effector of the EGFR pathway. Phosphorylation of (Figure 4a) , and the levels of TGF-a in culture media from the MKN-45 cells transfected with SPC18 siRNA1 or SPC18 siRNA2 were significantly lower than those from MKN-45 cells transfected with negative control siRNA (P ¼ 0.001 and P ¼ 0.001, respectively, unpaired Student's t-test) (Figure 4b ). We measured mRNA expression levels of TGF-a by qRT-PCR, however, mRNA expression levels of TGF-a in the MKN-45 cells transfected with SPC18 siRNA1 or SPC18 siRNA2 were similar to those in the MKN-45 cells transfected with negative control siRNA. EGF protein was not detected in culture media from the MKN-45 cells transfected with SPC18 siRNA or those transfected with negative control siRNA by ELISA. Microsome fraction, which included ER protein, was extracted, and the levels of TGF-a were measured by ELISA. As shown in Figure 4b , the levels of TGF-a in microsome fraction from the MKN-45 cells transfected with SPC18 siRNA1 or SPC18 siRNA2 were significantly higher than those from MKN-45 cells transfected with negative control siRNA (P ¼ 0.001 and P ¼ 0.001, respectively, unpaired Student's t-test). These results indicate that SCP18 is involved in maintaining TGF-a secretion in GC cells.
To investigate the possible antiproliferative effects of SPC18 knockdown, we performed an MTT assay 8 days after siRNA transfection (Figure 4c ). MKN-45 siRNA1-transfected and siRNA2-transfected MKN-45 cells showed significantly reduced viability relative to negative control siRNA-transfected MKN-45 cells (P ¼ 0.001 and P ¼ 0.001, respectively, unpaired Student's t-test). Next, to determine the possible role of SPC18 in the invasiveness of GC cells, we used a transwell invasion assay (Figure 4d ). On day 2, the invasiveness of SPC18-knockdown MKN-45 cells was B50% less than that of the negative control siRNA-transfected MKN-45 cells (P ¼ 0.007 and P ¼ 0.005, respectively, unpaired Student's t-test). However, as SPC18-knockdown cells showed significantly reduced cell viability, the cell number difference observed in the invasion assay may be caused by the reduced cell viability. 
DISCUSSION
In the present study, we built a small and focused oligonucleotide array on which 394 genes were selected based on our SAGE data and previously reported array data, and found that SEC11A, which encodes SPC18 protein, is overexpressed in GC. Although growth factors such as TGF-a and EGF have an important role in cancer cell growth, the possible effects of alteration to cellular secretion mechanisms on the secretion of these oncogenic factors have not been investigated. We showed that expression levels of SPC18 varied in association with tumor stage in both the Hiroshima and Chiba cohorts. Forced expression of SPC18 in the GC cell line promoted cancer cell growth in vitro and in vivo, and stimulated cancer cell invasion. Furthermore, forced expression of SPC18 induced TGF-a secretion. Knockdown of SPC18 by RNAi inhibited TGF-a secretion. Taken together, these results indicate that SPC18 is associated with GC cell progression rather than GC pathogenesis.
TGF-a is biosynthesized as a larger transmembrane protein termed pro-TGF-a (TGF-a precursor). 19, 20 TGF-a precursor contains an extracellular domain of B100 amino acids that includes the NH 2 -terminal signal sequence and the 50-amino acid TGF-a, a hydrophobic transmembrane domain, and a 35-residue cytoplasmic domain. 21 The NH 2 -terminal signal sequence allows translocation of the nascent polypeptide chain through the membrane of the ER. 19, 20 Three proteolytic events contribute to the complete maturation of the TGF-a precursor. The first event involves the removal of the signal peptide by signal peptidases. This occurs upon the precursor peptide's entry into the secretory route in the ER. In the present study, SPC18 inhibition by RNAi did not change mRNA expression levels of TGF-a in the MKN-45 cells, although SPC18 inhibition reduced TGF-a protein levels in culture media, suggesting that SPC18 overexpression does not upregulate TGF-a expression at the transcriptional level. We also confirmed that the levels of TGF-a in microsome fraction from the NKN-45 cells transfected with SPC18 siRNA1 or SPC18 siRNA2 were significantly higher than those from MKN-45 cells transfected with negative control siRNA. It is likely that SPC18 cleaves the signal peptide of TGF-a within the ER, and that the overexpression of SPC18 enhances secretion of TGF-a.
SPC reportedly has five distinct subunits 11 of which both SPC18 and SPC21 are presumed to have catalytic activity. 12 Although overexpression of SPC18 has frequently been found in GC tissue samples, overexpression of SPC21 was not detected in this study. These results led us to question whether overexpression of SPC18 alone is sufficient to induce high signal peptidase activity in SPC. We confirmed that the knockdown of SPC21 by RNAi inhibits TGF-a secretion in MKN-45 cells (data not shown), indicating that SPC21 is required for maximal signal peptidase activity of the SPC. In contrast, TGF-a secretion can be induced in MKN-1 GC cells by forced expression of SPC18, without SPC21 overexpression (data not shown), suggesting a requirement for further investigation to elucidate possible additional functions of SPC18, as well as interactions between SPC18 with other subunits of the SPC and other molecules involved in cellular secretion processes. The oligonucleotide array analysis in this study found that expression of six genes was significantly higher in GC at stage III/IV than GC at stage I/II. Among these genes, MMP7, which encodes matrilysin, has been reported to be associated with cancer cell invasion.
14 TDGF1, which encodes cripto protein, has been reported to be involved in cancer cell proliferation, migration, epithelial-to-mesenchymal transition and in stimulation of tumor angiogenesis. 22 However, the significance of DDOST, NDUFB7 and SUPT4H1 remains unclear. DDOST has been reported to be associated with cancer cell metastasis by microarray analysis.
6
NDUFB7and SUPT4H1 were reported to be overexpressed in GC in our SAGE analysis. 2 To further our understanding of the role of these genes in GC, detailed expression analysis using methods such as qRT-PCR or immunohistochemical analysis should be performed.
In summary, we found that SPC18 is overexpressed in GC. We also showed that SPC18 contributes to malignant progression by promotion of TGF-a secretion in GC. SPC18 expression was not an independent prognostic indicator, and, as a result, SPC18 may not be suitable as a biomarker to identify patients with poor prognosis. In contrast, knockdown of SPC18 by RNAi inhibits TGF-a secretion, indicating that secretion of other growth factors promoting cancer cell growth may be inhibited by SPC18 knockdown. Specific inhibitors of SPC18 may constitute promising anticancer drugs.
MATERIALS AND METHODS

Tissue samples
In all, 1164 primary tumors were collected from patients diagnosed with GC. The samples were obtained during surgery at the Hiroshima University Hospital or an affiliated hospital. We confirmed microscopically that the tumor specimens were predominantly (480%) cancer tissue. Samples were frozen immediately in liquid nitrogen and stored at À 80 1C until use. Twenty-five GC samples and corresponding non-neoplastic mucosal samples were obtained for use in our oligonucleotide array analysis.
For qRT-PCR analysis, the noncancerous samples of heart, lung, stomach, small intestine, colon, liver, pancreas, kidney, bone marrow, peripheral leukocytes, spleen, skeletal muscle, brain and spinal cord were purchased from Clontech (Palo Alto, CA, USA). In total, fifty-one GC samples and corresponding non-neoplastic mucosa samples were used for qRT-PCR analysis.
For immunohistochemical analysis, we used archival formalin-fixed, paraffin-embedded tissues from 1088 patients who had undergone surgical excision of GC. Of these patients, 99 had been treated at the Hiroshima University Hospital, Hiroshima, Japan (Hiroshima cohort); the remaining 989 were treated at the National Cancer Center Hospital East, Chiba, Japan (Chiba cohort). Immunohistochemical analysis was performed using whole paraffin-embedded blocks for the Hiroshima cohort and tissue microarray for the Chiba cohort. 23 This study was approved by the Ethical Committee for Human Genome Research of Hiroshima University and the institutional review board of the National Cancer Center.
Cell lines, expression vector, transfection and TGF-a treatment MKN-1 and MKN-45 GC cell lines were provided by Dr Toshimitsu Suzuki. 24 All cell lines were maintained in RPMI 1640 (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) containing 10% fetal bovine serum (BioWhittaker, Walkersville, MD, USA) in a humidified atmosphere of 5% CO 2 and 95% air at 37 1C. For constitutive expression of the SEC11A gene, cDNA was PCR amplified and subcloned into pcDNA 3.1 (Invitrogen Corp., Carlsbad, CA, USA) in-frame with a NH 2 -terminal (pcDNA-V5-SPC18) V5 epitope tag. Transient transfection was carried out with FuGENE6 Transfection Reagent (Roche Diagnostics, Indianapolis, IN, USA). After 24 h of serum starvation, 100 nM concentration of TGF-a (Sigma, St Louis, MO, USA) was added.
Oligonucleotide array construction and data analysis
The 70-nucleotide oligonucleotides were synthesized with amino-modified 5 0 termini (Oligator Human Refset, Illumina, San Diego, CA, USA). The oligonucleotides were dissolved in 40 ml of Solution I (Takara Bio Inc., Shiga, Japan), and then spotted in triplicate onto glass slides (Hubble Slide, Takara Bio Inc.) using a GMS 417 Arrayer (Affymetrix, Santa Clara, CA, USA). Slides were fixed in 0.2% SDS for 2 min and in 0.3 N NaOH for 5 min, then dehydrated with 100% cold ethanol for 3 min and finally air-dried. The array contained 394 genes, including GC-related genes identified by our previous SAGE analysis, 2 known genes related to development and progression of GC, [6] [7] [8] and genes associated with sensitivity to anticancer drugs. 9 A list of the genes on the array is available upon request. Preparation of labeled probe, hybridization, detection and data analysis were performed as described previously. 25 Antibodies
